Brain HealthFDA Approves Tavapadon for Parkinson's Disease in Adults
The FDA approved Juvmo (tavapadon) on September 25, 2026, for the treatment of Parkinson's disease in adults. Parkinson's is a common age-related neurodegenerative disease marked by the progressive loss of dopaminergic neurons, and it is a major contributor to loss of mobility and independence in later life. The source material consists only of the FDA approval listing and does not describe tavapadon's mechanism of action, pivotal trial results, or comparative tolerability data; those details are not addressed here. For a longevity-focused audience, any new therapeutic option for Parkinson's disease is relevant because the condition directly threatens late-life physical function and healthspan.
